HeartFlow Announces Decision by Centers for Medicare & Medicaid Services to Assign a New Technology Payment Classification to HeartFlow® FFRct Analysis
HeartFlow, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow® FFRct Analysis, a first-of-its-kind non-invasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). Under the APC payment system, hospitals enrolled in Medicare that bill CMS for the HeartFlow FFRct Analysis for Medicare patients will be eligible for reimbursement at a rate of $1,450.50 for the technical component of the test. This payment rate will take effect on January 1, 2018.
"The CMS decision to assign a New Technology APC for the HeartFlow FFRct Analysis is a major milestone and will ensure that our innovative, non-invasive technology can be utilized for Medicare beneficiaries. This is a significant development, given the high prevalence of CAD in people over age 65,” said John H. Stevens, M.D., president and chief executive officer of HeartFlow. “This decision is a testament to the wealth of clinical evidence and cost data that support the use of the HeartFlow FFRct Analysis as a critical, potentially life-saving technology.”
CAD, which today affects 16.8 million Americans,1 develops when the coronary arteries narrow, reducing blood flow to the heart and causing angina (chest pain), myocardial infarction (heart attack) and death. Older individuals are at highest risk of CAD.2 The HeartFlow FFRct Analysis provides insight into both the extent of CAD and the impact of the disease on blood flow to the heart. It uses high-quality images from a coronary computed tomography (CT) angiogram to provide clinicians with functional information in order to offer actionable information on the optimal course of treatment.
According to CMS, more than 55 million Americans are enrolled in the Medicare program.3
“CMS’s decision to assign a New Technology APC for FFRct technology for Medicare recipients is a recognition of the value of this technology and its demonstrated ability to reduce the number of invasive diagnostic coronary angiography procedures and help medical centers reduce costs,” said Pamela Douglas, M.D., Ursula Geller Professor for Research in Cardiovascular Disease in the School of Medicine at Duke University and past president of the American College of Cardiology. “The HeartFlow Analysis is an important tool in helping us assess patients with suspected coronary artery disease and better understand how their coronary blockages affect blood flow to the heart.”
“The decision by CMS will help in the diagnosis and treatment of patients with suspected CAD and means the number of patients over age 65 who will have access to this technology will significantly increase,” said Daniel Simon, M.D., president, University Hospitals (UH) Cleveland Medical Center, and professor of medicine at Case Western Reserve University School of Medicine. “At our center, the use of the HeartFlow FFRct Analysis is transforming how we diagnose and treat patients with coronary artery disease, helping us move closer to achieving the triple aim of improving the patient experience, improving the health of our patients, and reducing healthcare costs at our institution.”
Previously, the American Medical Association (AMA) issued a set of Category III Current Procedural Terminology (CPT®) codes for the HeartFlow FFRct Analysis. These codes provide evidence that the Analysis is a unique and distinct procedure that provides important and actionable clinical information above and beyond that of a coronary CT angiogram. Beginning on January 1, 2018, hospitals utilizing the HeartFlow FFRct Analysis will be able to generate claims when it is ordered for patients with suspected CAD via the use of specific CPT codes.
The CMS decision follows a growing number of commercial payers and professional organizations that have recognized its value in diagnosing patients with suspected CAD. Anthem, Aetna and other Blue Cross Blue Shield companies that collectively provide health insurance for approximately 80 million people have issued positive medical coverage decisions. Evidence Street, which conducts healthcare technology evaluations for the Blue Cross Blue Shield Association, a national federation of 36 independent Blue Cross and Blue Shield companies, issued a positive review. In the U.K., the National Institute for Health and Care Excellence (NICE) of the National Health Service, which covers 64.6 million lives, also issued positive guidance. The American College of Cardiology (ACC) and American Heart Association (AHA) released updated Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease. These criteria include the use of HeartFlow FFRct Analysis in determining the appropriateness of revascularization in many clinical scenarios.
About the HeartFlow FFRct Analysis
With HeartFlow’s technology, data from a patient’s non-invasive coronary CT angiogram are securely uploaded from the hospital’s system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D model of the patient’s coronary arteries. It then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The HeartFlow FFRct Analysis is provided to the patient’s physician via a secure web interface.
Clinicians around the world have chosen the HeartFlow FFRct Analysis for more than 15,000 patients to aid in the diagnosis of CAD. HeartFlow’s technology has been demonstrated to reduce unnecessary and invasive diagnostic coronary angiography procedures, and significantly reduce healthcare costs for hospitals.4
About HeartFlow, Inc.
HeartFlow, Inc. is transforming the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow® FFRct Analysis is the first available non-invasive solution that enables a physician to more appropriately evaluate whether an individual has significant coronary artery disease (CAD) based on both anatomy and physiology. The HeartFlow FFRct Analysis, which leverages deep learning to create a personalized 3D model of the patient’s arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve both clinical outcomes and the patient experience while reducing the cost of care. The HeartFlow FFRct Analysis is commercially available in the United States, Canada, Europe and Japan. For more information, visit www.heartflow.com.
4 Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45.
Chris B. Ernst, 415-710-9445
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Researchers and Scientists from Five Countries Named Winners of King Faisal Prize 201819.1.2018 13:33 | Tiedote
Five researchers and scientists from Malaysia, Jordan, Tunisia, the US and the UK have been named winners of the King Faisal Prize 2018 as the 40th edition of the renowned award recognized their distinguished contributions towards humanity. The Prize honours exceptional achievements in five categories: Service to Islam, Islamic Studies, Arabic Language & Literature, Medicine, and Science. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180119005245/en/ His Royal Highness Prince Khalid Al-Faisal, Chairman of King Faisal Prize Board, Abdulaziz (Photo: AETOSWire) Professor Irwandi Jaswir, Deputy Dean of the International Institute for Halal Research and Training (INHART) and Secretary of Council of Professors at the International Islamic University Malaysia (IIUM), has been named the winner in the Service to Islam category for contributions to the development of ‘Halal Science’ and Halal food and consumer goods. Professor Bashar
E.ON Chooses Corinex Broadband over Powerline Technology for their Smart Metering Rollout19.1.2018 09:00 | Tiedote
E.ON, an international energy company that serves 32 million customers across multiple countries, has decided to use broadband over powerline (BPL) as the key technology in their communication mix, in the smart metering communication infrastructure for the low voltage part of their grid. E.ON chose Corinex as the solution provider for the initial two years of the deployment. The initial deployment will be several ten thousands of repeaters and head ends providing secure communication for a couple of hundred thousands of households. Corinex Grid Value network management based on IBM Tivoli platform will manage the network. “After extensive field trials, we found that Corinex broadband over powerline technology meets our requirements for mass rollout of smart metering services. We are convinced BPL is ideally suited to address the needs of many other utilities, so E.ON is interested in supporting BPL industry standardization in order to create a broad ecosystem of silicon and system vend
Changes in Executive Management at Sosei19.1.2018 04:54 | Tiedote
Sosei Group Corporation (“Sosei” or the “Company”) (TOKYO: 4565), the world leader in GPCR medicine design and development, today announced that Dr. Fiona Marshall has resigned from her position as Executive Vice President and Chief Scientific Officer of Sosei to assume a senior role outside the Company. Dr. Marshall will leave Sosei at the end of February 2018. “As a co-founder of Heptares, I am very proud to have been associated with building a team of talented scientists over the past decade that has made many important breakthroughs in the field of GPCR stabilization and structure-based drug design, a unique technology that now underpins Sosei’s powerful drug discovery capability,” said Dr. Marshall. “With the team in excellent hands, I feel the time is right for me to move on to new challenges and I wish everyone at Sosei the best for what looks set to be an exciting future for the Company.” Peter Bains, Chief Executive Officer of Sosei, added: “Fiona has been a pivotal figure in
DXC Technology Named a 2018 Thomson Reuters Top 100 Global Technology Leader19.1.2018 02:12 | Tiedote
DXC Technology (NYSE: DXC) has been recognized as a 2018 Top 100 Global Technology Leader by Thomson Reuters. The inaugural program identifies the tech industry’s most operationally sound and financially successful organizations. The Thomson Reuters Top 100 Global Tech Leaders study, the industry’s first holistic assessment of today’s leading tech companies, utilizes a 28-point data-driven algorithm to objectively identify organizations positioned to thrive in a complex and changing business environment. The patent pending methodology, developed by the Thomson Reuters Boston Innovation Lab, is based on eight principal pillars of performance: Financial Performance, Management and Investor Confidence, Risk and Resilience, Legal Compliance, Innovation, People and Social Responsibility, Environmental Impact, and Reputation. According to Thomson Reuters, these are the companies whose final scores across the pillars outshine over 5,000 other technology companies around the world. “DXC Techno
IFF Honors Dominique Ropion with Prestigious Master Perfumer Title19.1.2018 00:15 | Tiedote
Regulatory News: This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180118006275/en/ Dominique Ropion (Photo: Business Wire) International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, has named Dominique Ropion Master Perfumer. The Company’s designation recognizes perfumers who have demonstrated consistent and outstanding levels of creativity and craftsmanship in the art of perfumery, and exceptional leadership in and measurable impact on the industry. Mr. Ropion is the second perfumer at IFF recognized with the prestigious title, which was established in 2013. “At the heart of IFF are the people who consistently go above and beyond to passionately pursue their art and by doing so, revolutionize the industry,” said IFF Chairman & CEO Andreas Fibig. “In his 17 years with us, Dominique has consistently achieved this outstanding level of creativity and p
The Securities & Exchange Commission Announces Several Judgments And Injunctions Entered Against Defendants In The SEC v. Benger, et al. Litigation18.1.2018 22:21 | Tiedote
The following statement is being issued by the Securities & Exchange Commission regarding Benger Fair Fund Class Action: Legal Notice BENGER FAIR FUND NOTICE The United States Securities and Exchange Commission authorized this Notice. This is not a solicitation from a lawyer. If you purchased or otherwise acquired China Voice Holding Corp., Biomoda, Inc., Pharma Holdings Inc., World Energy Solutions, Inc., Revolutions Medical Corp., Earthsearch Communications, Inc., and Essential Innovations Technology Corp. common shares from Defendants outside of the United States between March 1, 2007 and February 28, 2009, inclusive (the “Relevant Period”), you may be entitled to receive a monetary payment from the Benger Fair Fund (“Fair Fund”). Background In the action titled Securities and Exchange Commission v. Benger, et al. pending in the United States District Court for the Northern District of Illinois, Case No. 09-CV-676, several judgments and injunctions were entered against defendants Ha
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme